SAFETY DATA SHEET

Ceilcote 370HT Primer Part A

Section 1. Chemical product and company identification

GHS product identifier

: Ceilcote 370HT Primer Part A

Product code

: NCA067

Relevant identified uses of the substance or mixture and uses advised against

	Identified uses		
Professional application of coatings and inks			
Uses a	dvised against	Reason	
All Other Uses			
Supplier's details	: International Farg AB Holmedalen 3 Aspereds Industriomrade SE-424 22 Angered Sweden Tel: +46 (0) 31 928500 Fax: +4	6 (0) 31 928530	
Emergency telephone number (with hours of operation)	: +46 8 33 12 31		
National advisory body/ Poison Centre (For use only	: 8-10-1-202-625-3333 / 8-10-1-202	2-784-4660	

by licensed medical	
<u>professionals.)</u>	
e-mail address of person	: sdsfellinguk@akzonobel.com
responsible for this SDS	
•	

International Paint Ltd (Ukraine), 5 Solnechnaya Str, Odessa, Ukraine

Tel: +380 482 346308 / 347417 Fax: +380 482 346 307

Section 2. Hazards identification

Classification of the substance or mixture	: FLAMMABLE LIQUIDS - Category 3 ACUTE TOXICITY (inhalation) - Category 4 SKIN CORROSION/IRRITATION - Category 2 SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 1 TOXIC TO REPRODUCTION (Unborn child) - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 SPECIFIC TARGET ORGAN TOXICITY (PEPEATED EXPOSURE) (hearing
	SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) (hearing organs) - Category 1

GHS label elements



Section 2. Hazards identification

Hazard pictograms	
Signal word	: Danger
Hazard statements	 Flammable liquid and vapour. Harmful if inhaled. Causes serious eye damage. Causes skin irritation. Suspected of damaging the unborn child. May cause respiratory irritation. Causes damage to organs through prolonged or repeated exposure. (hearing organs)
Precautionary statements	
Prevention	: Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Wear protective gloves. Wear eye or face protection. Wear protective clothing. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Use explosion-proof electrical, ventilating, lighting and all material-handling equipment. Use only non-sparking tools. Take precautionary measures against static discharge. Keep container tightly closed. Use only outdoors or in a well-ventilated area. Avoid breathing vapour. Do not eat, drink or smoke when using this product. Wash hands thoroughly after handling. Do not breathe gas, vapour or spray.
Response	: Get medical attention if you feel unwell. IF exposed or concerned: Get medical attention. IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER or physician if you feel unwell. IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water or shower. IF ON SKIN: Wash with plenty of soap and water. Take off contaminated clothing and wash it before reuse. If skin irritation occurs: Get medical attention. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER or physician.
Storage	: Store locked up. Store in a well-ventilated place. Keep cool.
Disposal	 Dispose of contents and container in accordance with all local, regional, national and international regulations.
Supplemental label elements	: Wear appropriate respirator when ventilation is inadequate.

Other hazards which do not : None known. result in classification

Section 3. Composition/information on ingredients

Substance/mixture

: Mixture

Ingredient name	% by weight	CAS number	Classification
styrene	≥25 - ≤50	100-42-5	Flam. Liq. 3, H226 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2A, H319 Repr. 2, H361 (Unborn child) STOT RE 1, H372 (hearing organs)
methacrylic acid	<5	79-41-4	Flam. Liq. 4, H227 Acute Tox. 4, H302
Date of issue/Date of revision	: 31/05/2017	I	AkzoNobel

2/13

Section 3. Composition/information on ingredients

	Acute Tox. 3, H311 Skin Corr. 1A, H314 STOT SE 3, H335
--	--

XInternational

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

Description of necessary first aid measures		
Eye contact	: Get medical attention immediately. Call a poison center or physician. Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician.	
Inhalation	: Get medical attention immediately. Call a poison center or physician. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.	
Skin contact	: Get medical attention immediately. Call a poison center or physician. Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Chemical burns must be treated promptly by a physician. Wash clothing before reuse. Clean shoes thoroughly before reuse.	
Ingestion	: Get medical attention immediately. Call a poison center or physician. Wash out mouth with water. Remove dentures if any. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Chemical burns must be treated promptly by a physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.	
Most important symp	toms/effects, acute and delayed	

Potential acute health effectsEye contact: Causes serious eye damage.Inhalation: Harmful if inhaled. May cause respiratory irritation.Skin contact: Causes skin irritation.Ingestion: Irritating to mouth, throat and stomach.Over-exposure signs/symptomsEye contact: Adverse symptoms may include the following:
pain
watering
redness

AkzoNobel

Section 4. First aid measures

Inhalation	: Adverse symptoms may include the following:
	respiratory tract irritation
	coughing
	headache
	drowsiness/fatigue
	dizziness/vertigo
	muscle weakness
	unconsciousness
	reduced foetal weight increase in foetal deaths
	skeletal malformations
01.1	
Skin contact	: Adverse symptoms may include the following:
	pain or irritation redness
	blistering may occur
	reduced foetal weight
	increase in foetal deaths
	skeletal malformations
Ingestion	: Adverse symptoms may include the following:
0	stomach pains
	reduced foetal weight
	increase in foetal deaths
	skeletal malformations
dication of immediate r	nedical attention and special treatment needed, if necessary
Notes to physician	: Treat symptomatically. Contact poison treatment specialis
	, F

Notes to physician	: Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training. If i is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.

See toxicological information (Section 11)

Section 5. Firefighting measures

Extinguishing media		
Suitable extinguishing media	: Use dry chemical, CO ₂ , water spray (fog) or foam.	
Unsuitable extinguishing media	: Do not use water jet.	
Specific hazards arising from the chemical	: Flammable liquid and vapour. In a fire or if heated, a pressure increase will occur and the container may burst, with the risk of a subsequent explosion. Runoff to sewer may create fire or explosion hazard.	
Hazardous thermal decomposition products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide	
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident i there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.	f
Special protective equipment for fire-fighters	 Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. 	
Date of issue/Date of revision Version : 3	: 31/05/2017 AkzoNobel	

X.International.

Section 6. Accidental release measures

Personal precautions, protective equipment and emergency procedures : No action shall be taken involving any personal risk or without suitable training. For non-emergency Evacuate surrounding areas. Keep unnecessary and unprotected personnel from personnel entering. Do not touch or walk through spilt material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Do not breathe vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment. **For emergency responders** : If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel". : Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains **Environmental precautions** and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Methods and material for containment and cleaning up Small spill : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor. Large spill : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations (see Section 13). Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. Note: see Section 1 for emergency contact information and Section 13 for waste disposal.

Section 7. Handling and storage

Precautions for safe handling	
Protective measures	: Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

AkzoNobel

Section 7. Handling and storage

Conditions for safe storage, including any incompatibilities	:	Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Vapours are heavier than air and may spread along floors. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.
--	---	--

Section 8. Exposure controls/personal protection

Control parameters

Occupational exposure limits

Ingredient name		Exposure limits
styrene methacrylic acid		РО МинЗдраСоц ПДК (Russian Federation, 9/2011). TWA: 10 mg/m ³ 8 hours. Form: vapor and/ or gases CEIL: 30 mg/m ³ Form: vapor and/or gases РО МинЗдраСоц ПДК (Russian Federation, 9/2011).
		CEIL: 10 mg/m ³ Form: vapor and/or gases
Appropriate engineering controls	ventilation or other engineerir contaminants below any reco	ation. Use process enclosures, local exhaust g controls to keep worker exposure to airborne mmended or statutory limits. The engineering controls r or dust concentrations below any lower explosive entilation equipment.
Environmental exposure controls	they comply with the requiren cases, fume scrubbers, filters	work process equipment should be checked to ensure ents of environmental protection legislation. In some or engineering modifications to the process o reduce emissions to acceptable levels.
Individual protection measu	res	
Hygiene measures	eating, smoking and using the Appropriate techniques shoul	the thoroughly after handling chemical products, before e lavatory and at the end of the working period. d be used to remove potentially contaminated clothing. Defore reusing. Ensure that eyewash stations and the workstation location.
Eye/face protection	assessment indicates this is in gases or dusts. If contact is punless the assessment indicates t	h an approved standard should be used when a risk necessary to avoid exposure to liquid splashes, mists, possible, the following protection should be worn, tes a higher degree of protection: chemical splash inhalation hazards exist, a full-face respirator may be
Skin protection		
Hand protection	against chemicals and micro- When prolonged or frequently class of 6 (breakthrough time recommended. When only br of 2 or higher (breakthrough t recommended. The user mu for handling this product is the particular conditions of use, a The selection of a specific glo	s classified under Standard EN 374: Protective gloves organisms. Recommended: Viton® or Nitrile gloves. repeated contact may occur, a glove with a protection greater than 480 minutes according to EN 374) is ef contact is expected, a glove with a protection class ime greater than 30 minutes according to EN 374) is st check that the final choice of type of glove selected e most appropriate and takes into account the s included in the user's risk assessment. NOTICE: ve for a particular application and duration of use in a to account all relevant workplace factors such as, but
Date of issue/Date of revision Version : 3	: 31/05/2017	AkzoNobel

X.International.

Section 8. Exposure controls/personal protection

	not limited to: Other chemicals which may be handled, physical requirements (cut/ puncture protection, dexterity, thermal protection), potential body reactions to glove materials, as well as the instructions/specifications provided by the glove supplier. Barrier creams may help to protect the exposed areas of the skin but should not be applied once exposure has occurred.
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves.
Other skin protection	 Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.

Section 9. Physical and chemical properties

-	
<u>Appearance</u>	
Physical state	: Liquid.
Colour	: Purple.
Odour	: Sweetish.
Odour threshold	Not available.
рН	Not applicable.
Melting point	Not available.
Boiling point	: Lowest known value: 145°C (293°F) (styrene).
Flash point	Closed cup: 28°C (82.4°F)
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.
Lower and upper explosive (flammable) limits	Greatest known range: Lower: 0.9% Upper: 6.8% (styrene)
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	: 1.08
Solubility	Insoluble in the following materials: cold water.
Partition coefficient: n- octanol/water	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	: Kinematic (room temperature): 694 mm ² /s (694 cSt)

Section 10. Stability and reactivity

Reactivity	: No specific test data related to reactivity available for this product or its ingredients.	
Chemical stability	: The product is stable.	
Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.	
Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld braze, solder, drill, grind or expose containers to heat or sources of ignition.	,
Date of issue/Date of revision Version : 3	: 31/05/2017 AkzoNobel	

Section 10. Stability and reactivity

Incompatible materials	: Reactive or incompatible with the following materials:
	oxidizing materials

Hazardous decomposition : Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

Information on toxicological effects

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
styrene	LC50 Inhalation Gas. LC50 Inhalation Vapour	Rat Rat	2770 ppm 11800 mg/m³	4 hours 4 hours
methacrylic acid	LD50 Oral LD50 Dermal LD50 Oral	Rat Rabbit Rat	2650 mg/kg 500 mg/kg 1060 mg/kg	- -

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
styrene	Eyes - Mild irritant	Human	-	50 parts per million	-
	Eyes - Moderate irritant	Rabbit	-	24 hours 100 milligrams	-
	Eyes - Severe irritant	Rabbit	-	100 milligrams	-
	Skin - Mild irritant	Rabbit	-	500 milligrams	-
	Skin - Moderate irritant	Rabbit	-	100 Percent	-

Sensitisation

Not available.

Mutagenicity

Not available.

Carcinogenicity

Not available.

Reproductive toxicity

Not available.

Teratogenicity

Not available.

Specific target organ toxicity (single exposure)

Name	0,	Route of exposure	Target organs
methacrylic acid	Category 3	Not applicable.	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Name	Category	Route of exposure	Target organs
styrene	Category 1	Not determined	hearing organs

Aspiration hazard

Not available.



X.International.

Section 11. Toxicological information

Information on likely routes : Not available. of exposure Potential acute health effects Eye contact : Causes serious eye damage. Inhalation : Harmful if inhaled. May cause respiratory irritation. Skin contact : Causes skin irritation. Ingestion : Irritating to mouth, throat and stomach. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain watering respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal maiformations Skin contact : Adverse symptoms may include the following: respiration tract irritation reduces bilstering may occur bilstering may occur bilstering may occur increase in foetal deaths skeletal maiformations Ingestion : Adverse symptoms may include the following: reduced foetal weight increase in foetal deaths skeletal maiformations Delayed and immediate : Not available. effects		
Eye contact : Causes serious eye damage. Inhalation : Harmful if inhaled. May cause respiratory irritation. Skin contact : Causes skin irritation. Ingestion : Irritating to mouth, throat and stomach. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coupling headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation redness bilistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential deaths skeletal malformations Potential immediate : Not available. effects Potential delayed effects Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available.		Not available.
Inhalation : Harmful if inhaled. May cause respiratory irritation. Skin contact : Causes skin irritation. Ingestion : Irritating to mouth, throat and stomach. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate effects : Not available. Potential delayed effects : Not available. Long term exposure Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects<	Potential acute health effects	
Skin contact : Causes skin irritation. Ingestion : Irritating to mouth, throat and stomach. Symptoms related to the physical. chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation redness Distering may occur reduced foetal weight increase in foetal deaths skeletal malformations Bistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential deagved effects : Potential deagved effects : Potential delayed effects : Potential delayed effects	Eye contact :	Causes serious eye damage.
Ingestion : Initiating to mouth, throat and stomach. Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain o irritation reduces foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain o irritation reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential delayed effects : Not available. Eng term exposure : Potential delayed effects Potential delayed effects : Not available. Eng term exposure : Potential chronic health effects Potential delayed effects : Not available. Effects : Not available.	Inhalation :	Harmful if inhaled. May cause respiratory irritation.
Symptoms related to the physical, chemical and toxicological characteristics Eye contact : Adverse symptoms may include the following: pain watering redness Inhalation :: Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact :: Adverse symptoms may include the following: pain or irritation reduces foetal weight increase in foetal deaths skeletal malformations Ingestion :: Adverse symptoms may include the following: skeletal malformations Ingestion :: Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Ingestion :: Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate effects : Not available. Potential immediate effects : Not available. Potential idelayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available.	Skin contact :	Causes skin irritation.
Eye contact : Adverse symptoms may include the following: pain watering redness Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing headache dirowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation redness bilstering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: spain or irritation reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects : Not available. effects : Potential immediate : Not available. effects : Potential delayed effects : Not available. effects : Potential delayed effects : Not available. effects : Potential delayed effects : Not a	Ingestion :	Irritating to mouth, throat and stomach.
pain watering redness Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations Ingestion : Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential immediate : Not available. Long term exposure Potential delayed effects : Not available. Effects	Symptoms related to the physi	cal, chemical and toxicological characteristics
inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal maiformations Skin contact : Adverse symptoms may include the following: pain or irritation redness bilistering may occur reduced foetal weight increase in foetal deaths skeletal maiformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal maiformations bilistering may occur reduced foetal weight increase in foetal deaths skeletal maiformations bilistering stomach pains reduced foetal weight increase in foetal deaths skeletal maiformations bilistering stomach pains steletal maiformations steletal maiformations steletal maiformatio	Eye contact :	Adverse symptoms may include the following:
Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal maiformations Skin contact : Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal maiformations Ingestion : Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal maiformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal maiformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential delayed effects Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not		•
Inhalation : Adverse symptoms may include the following: respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduces foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduces foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential delayed effects : Not available. Long term exposure Potential delayed effects : Not available. Potential delayed effects : Not available. effects Potential delayed effects : Not available. Potential delayed effects : <t< th=""><th></th><th>-</th></t<>		-
respiratory tract irritation coughing headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduces foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential immediate is Not available. effects Potential delayed effects : Not available. Eng term exposure Potential delayed effects : Not available. effects Potential delayed effects : Not available. Potential delayed effects : Not available. effects Potential delayed effects : Not available. Potential delayed effects : Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.	Inhalation	
coughing headache headache drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: steletal malformations bilstering may occur Ingestion : Adverse symptoms may include the following: steletal malformations skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate : Not available. - effects : Potential delayed effects : Potential delayed effects : Not available. -	initialation .	
drowsiness/fatigue dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not av		
dizziness/vertigo muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations Skin contact Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations Ingestion Adverse symptoms may include the following: stormach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate Not available. effects Indicate as well as chronic effects from short and long-term exposure Potential delayed effects Inot available. effects Inot available. effects Inot available. Potential chronic health effects Inot available. Potential delayed effects		
muscle weakness unconsciousness reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity Mutagenicity : No known significant effects or critical hazards.		
reduced foetal weight increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation redness blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: store symptom sy		
increase in foetal deaths skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation redness blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential immediate = Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate = Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. effects Potential delayed effects : Not available. effects Potential chronic health effects Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		
skeletal malformations Skin contact : Adverse symptoms may include the following: pain or irritation redness blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential immediate effects : Not available. Long term exposure Potential delayed effects : Not available. Potential immediate : Not available. Potential delayed effects : Not available. Potential immediate : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity Mutagenicity : No known significant effects or critical hazards.		•
Skin contact : Adverse symptoms may include the following: pain or irritation redness blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: steletal malformations Ingestion : Adverse symptoms may include the following: steletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential immediate : Not available. effects : Not available. effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : N		
pain or irritation redness blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential chronic health effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity Mutagenicity : No known significant effects or critical hazards.	Skin contact :	
blistering may occur reduced foetal weight increase in foetal deaths skeletal malformations Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exp Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. effects Potential chronic health effects Not available. effects Potential chronic health effects Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity :		
reduced foetal weight increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Endition term exposure : Not available. Potential delayed effects : Not available. Endit term exposure : Not available. Potential delayed effects : Not available. Endit term exposure : Not available. Potential delayed effects : Not available. effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity Mutagenicity : No known significant effects or critical hazards.		
increase in foetal deaths skeletal malformations Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential chronic health effects : Not available. Potential chronic health effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity in No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		
Ingestion : Adverse symptoms may include the following: stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Potential immediate effects Potential immediate : Not available. effects Potential delayed effects : Not available. effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity i. No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		-
stomach pains reduced foetal weight increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		
Pelayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential chronic health effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.	Ingestion :	
increase in foetal deaths skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		
Skeletal malformations Delayed and immediate effects as well as chronic effects from short and long-term exposure Short term exposure Potential immediate : Not available. effects Potential delayed effects : Not available. Long term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		
Short term exposure Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential ble. : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		
Short term exposure Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Long term exposure : Not available. Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Potential ble. : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		
Potential immediate effects: Not available.Potential delayed effects remexposure: Not available.Potential immediate effects: Not available.Potential delayed effects effects: Not available.Potential delayed effects effects: Not available.Potential delayed effects effects: Not available.Potential delayed effects effects: Not available.Potential chronic health effects Not available.: Not available.General Carcinogenicity Mutagenicity: Causes damage to organs through prolonged or repeated is No known significant effects or critical hazards.		as well as chronic effects from short and long-term exposure
effectsPotential delayed effects: Not available.Long term exposure.Potential immediate: Not available.effects.Potential delayed effects: Not available.Potential chronic health effects.Not availableGeneral: Causes damage to organs through prolonged or repeatedCarcinogenicity: No known significant effects or critical hazards.Mutagenicity: No known significant effects or critical hazards.		
Long term exposure Potential immediate : Not available. effects : Not available. Potential delayed effects : Not available. Potential chronic health effects : Not available. Not available. : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.		Not available.
Potential immediate effects: Not available.Potential delayed effects: Not available.Potential chronic health effectsNot available.General Carcinogenicity: Causes damage to organs through prolonged or repeatedMutagenicity: No known significant effects or critical hazards.Mutagenicity: No known significant effects or critical hazards.	Potential delayed effects :	Not available.
effects Potential delayed effects : Not available. Potential chronic health effects Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.	<u>Long term exposure</u>	
Potential delayed effects : Not available. Potential chronic health effects Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.	Potential immediate :	Not available.
Potential chronic health effects Not available. General : Causes damage to organs through prolonged or repeated Carcinogenicity : No known significant effects or critical hazards. Mutagenicity : No known significant effects or critical hazards.	•••••	
Not available.General: Causes damage to organs through prolonged or repeatedCarcinogenicity: No known significant effects or critical hazards.Mutagenicity: No known significant effects or critical hazards.	· · · · · · · · · · · · · · · · · · ·	
General: Causes damage to organs through prolonged or repeatedCarcinogenicity: No known significant effects or critical hazards.Mutagenicity: No known significant effects or critical hazards.		ts
Carcinogenicity: No known significant effects or critical hazards.Mutagenicity: No known significant effects or critical hazards.	Not available.	
Carcinogenicity: No known significant effects or critical hazards.Mutagenicity: No known significant effects or critical hazards.	General :	Causes damage to organs through prolonged or repeated exposu
Mutagenicity : No known significant effects or critical hazards.		
	• •	-
		-
	<u> </u>	

9/13



exposure.



Section 11. Toxicological information

Developmental effects Fertility effects

- : No known significant effects or critical hazards.
- : No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

Route	ATE value
Oral	21915.4 mg/kg
Dermal	10337.4 mg/kg
Inhalation (gases)	8015.9 ppm
Inhalation (vapours)	34.15 mg/l

Section 12. Ecological information

Toxicity

Product/ingredient name	Result	Species	Exposure
styrene	Acute EC50 1400 µg/l Fresh water	Algae - Pseudokirchneriella subcapitata	72 hours
	Acute EC50 720 µg/l Fresh water	Algae - Pseudokirchneriella subcapitata	96 hours
	Acute EC50 4700 to 7400 µg/l Fresh water	Daphnia - Daphnia magna	48 hours
	Acute LC50 13000 µg/l Fresh water	Crustaceans - Hyalella azteca	48 hours
	Acute LC50 4.7 mg/l Fresh water	Fish - Lepomis macrochirus	96 hours
	Chronic NOEC 63 µg/l Fresh water	Algae - Pseudokirchneriella subcapitata	96 hours
methacrylic acid	Chronic NOEC 53 mg/l Fresh water	Daphnia - Daphnia magna - Neonate	21 days

Persistence and degradability

Not available.

Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
styrene	0.35	13.489628825	low
methacrylic acid	0.93	-	low

Mobility in soil

Soil/water partition : Not available. coefficient (Koc)

Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

Disposal methods: The generation of waste should be avoided or minimised wherever possible.
Disposal of this product, solutions and any by-products should at all times comply
with the requirements of environmental protection and waste disposal legislation
and any regional local authority requirements.
Dispose of surplus and non-recyclable products via a licensed waste disposal
contractor. Waste should not be disposed of untreated to the sewer unless fully
compliant with the requirements of all authorities with jurisdiction. Waste packaging
should be recycled. Incineration or landfill should only be considered when recycling
is not feasible. This material and its container must be disposed of in a safe way.



Section 13. Disposal considerations

Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

Section 14. Transport information

	ADR/RID	IMDG	ΙΑΤΑ
UN number	UN1263	UN1263	UN1263
UN proper shipping name	PAINT	PAINT	PAINT
Transport hazard class(es)	3	3	3
Packing group	111	111	111
Environmental hazards	No.	No.	No.
Additional information	Special provisions 640 (E) Tunnel code (D/E)	-	-

IMDG Code Segregation : Not applicable. group

Special precautions for user : Transport within user's premises: always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

Section 15. Regulatory information

: No known specific national and/or regional regulations applicable to this product Safety, health and environmental regulations (including its ingredients). specific for the product

11/13

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals

Not listed.

Montreal Protocol (Annexes A, B, C, E)

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Inform Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals



Section 15. Regulatory information

Not listed.

Section 16. Other information

Justification

Classification			Justification	
FLAMMABLE LIQUIDS - Category 3 ACUTE TOXICITY (inhalation) - Category 4 SKIN CORROSION/IRRITATION - Category 2 SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 1 TOXIC TO REPRODUCTION (Unborn child) - Category 2 SPECIFIC TARGET ORGAN TOXICITY (SINGLE EXPOSURE) (Respiratory tract irritation) - Category 3 SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) (hearing organs) - Category 1		Category 4 I - Category 2 RRITATION - Category 1 nborn child) - Category 2 XICITY (SINGLE ritation) - Category 3 XICITY (REPEATED	On basis of test data Calculation method Calculation method Calculation method Calculation method Calculation method Calculation method	
History			•	
Date of printing	:	31/05/2017		
Date of issue/Date of revision	:	31/05/2017		
Date of previous issue	:	10/06/2016		
Version	:	3		
Key to abbreviations	:	ADN = European Provisions concerning the International Carriage of Dangerous Goods by Inland Waterway ADR = The European Agreement concerning the International Carriage of Dangerous Goods by Road ATE = Acute Toxicity Estimate BCF = Bioconcentration Factor GHS = Globally Harmonized System of Classification and Labelling of Chemicals IATA = International Air Transport Association IBC = Internediate Bulk Container IMDG = International Maritime Dangerous Goods LogPow = logarithm of the octanol/water partition coefficient MARPOL = International Convention for the Prevention of Pollution From Ships, 1973 as modified by the Protocol of 1978. ("Marpol" = marine pollution) RID = The Regulations concerning the International Carriage of Dangerous Goods by Rail UN = United Nations		
References	:	Not available.		

Indicates information that has changed from previously issued version.

Notice to reader

IMPORTANT NOTE: the information contained in this data sheet (as may be amended from time to time) is not intended to be exhaustive and is presented in good faith and believed to be correct as of the date on which it is prepared. It is the user's responsibility to verify that this data sheet is current prior to using the product to which it relates.

Persons using the information must make their own determinations as to the suitability of the relevant product for their purposes prior to use. Where those purposes are other than as specifically recommended in this safety data sheet, then the user uses the product at their own risk.

MANUFACTURER'S DISCLAIMER: the conditions, methods and factors affecting the handling, storage, application, use and disposal of the product are not under the control and knowledge of the manufacturer. Therefore the manufacturer does not assume responsibility for any adverse events which may occur in the handling, storage, application, use, misuse or disposal of the product and, so far as permitted by applicable law, the manufacturer expressly disclaims liability for any and all loss, damages and/or expenses arising out of or in any way connected to the storage, handling, use or disposal of the product. Safe handling, storage, use and disposal are the responsibility of the users. Users must comply with all applicable health and safety laws.



Section 16. Other information

Unless we have agreed to the contrary, all products are supplied by us subject to our standard terms and conditions of business, which include limitations of liability. Please make sure to refer to these and / or the relevant agreement which you have with AkzoNobel (or its affiliate, as the case may be). © AkzoNobel

13/13

